HOUSTON, April 27, 2023 — Golden Section is thrilled to announce our recent investment in Sinecure, a talent discovery platform that leverages AI-powered products to deliver highly qualified and diverse candidates for organizations. We led the $2.5 million round with the majority of funding going to enable increased activity in marketing and sales. As a B2B SaaS focused venture capital firm, we’re excited to partner with Sinecure to help transform the recruiting process through their innovative and holistic approach to talent discovery.

What excites us most about Sinecure is their focus on identifying and vetting candidates who possess the exact skills, knowledge, and experience required for a particular job opening. Their machine learning algorithms and analysis of personality traits, work style, and other motivators help to predict performance and career potential. This, in turn, helps organizations to find and retain top talent, driving growth and success well into the future.

We’re looking forward to the launch of Sinecure’s new products in 2023, including career trajectory-based candidate search and their plans to launch FOMO, a marketplace for contract and freelance talent, and new product collaboration software.

As part of our partnership, we’ll be working closely with Sinecure to provide guidance on product development and strategy, drawing on our expertise in early-stage investments and business development. We’re committed to working together with Sinecure’s leadership team and contributing to their mission of improving the recruiting process for all organizations.

We’ll be actively involved in helping Sinecure to realize its vision of disrupting the traditional recruiting process. We’re excited about the journey ahead and look forward to supporting the team every step of the way.

Sinecure
New York, NY
sinecure.ai

Golden Section
Houston, Texas
goldensection.com

Media Contact:
Yosef Levenstein, CMO at Golden Section
[email protected]

SOURCE Golden Section

Investment firm provides value-add capital solutions to growth-stage companies in Media, Entertainment, and Gaming

NEW YORK, April 27, 2023 — Alignment Growth announced the successful closing of Alignment Growth Fund I, its inaugural $360 million growth equity fund. Led by Alex Iosilevich, Kevin Tsujihara, and Jeff Bewkes, Alignment Growth invests in growth-stage media, entertainment, and gaming (“MEG”) companies, leveraging its team’s unique operating, strategic, and dealmaking expertise to drive value creation.

Since Alignment Growth’s launch in 2021, the firm has focused on investment opportunities with the latent capacity to revolutionize the MEG landscape, from disruptive platforms to creators and owners of powerful IP. Taking a highly engaged approach, Alignment Growth partners with management teams and founders to help achieve their global growth ambitions, optimize operations and corporate governance, and create lasting shareholder value.

“We founded Alignment Growth to address a tremendous whitespace in growth-stage investing,” said Alex Iosilevich. “The ecosystem is dominated by ‘deal-per-day’ mega-funds who cannot dedicate the time and resources to support each portfolio company in the way we do. We aim to fill the need for a highly engaged strategic advisor and source of value-added capital at every phase of a partnership.”

With over $100 million deployed to date, Alignment Growth’s investments include Fever, a live entertainment discovery platform; Crunchbase, a media information company and prospecting platform built on best-in-class company data; Spyglass Media Group, a global premium content company; and Build a Rocket Boy, a global video game developer focused on the future of AAA games.

“Alignment Growth’s approach is rooted in our team’s complementary experience in MEG strategy, operations, and dealmaking,” said Jeff Bewkes. “We invest in companies that can benefit from and grow with the added value of our team’s expertise.”

Fever Co-Founder and CEO Ignacio Bachiller Ströhlein concurs. “Alignment Growth’s depth of engagement, experience, and connectivity in the MEG industry has far exceeded our expectations and differentiated Alignment Growth from a traditional investor.”

About Alignment Growth

Alignment Growth invests in growth-stage companies across media, entertainment, and gaming on a global scale. Alignment Growth seeks to drive value creation in partnership with its portfolio companies by leveraging its team’s senior executive operating, strategic, and dealmaking experience at global Fortune 500 MEG companies. Additional details are available at alignmentgrowth.com.  

SOURCE Alignment Growth

RALEIGH, N.C. , April 27, 2023 — Car Space, a premier luxury coworking space and private social club, announced today that it has closed a $1.5 million seed capital raise to launch Car Space Raleigh and begin development of Car Space Charlotte and Car Space Charleston.  The investment is led by California-based HyperNFT and includes a partnership to display hypercars in Car Space’s North Carolina club locations. This round brings Car Space’s total funding to approximately $2.7 million.

This investment comes as the Car Space Raleigh location is within two months of grand opening. Car Space has developed a first-of-its-kind concept that combines the best of both worlds: a state-of-the-art coworking and office space and a private social club for car enthusiasts. The club offers a range of exclusive benefits, including a cocktail lounge, hospitality amenities, and access to exclusive events and activities. The investment and partnership will support continued growth into new markets in the US.

“At HyperNFT, we don’t settle for the status quo. We seek out and proudly partner with the most innovative and boundary-pushing businesses out there. CAR SPACE has proven to us through their impressive business partnerships and member growth that it is the epitome of what we look for in a partner. We’re also thrilled to showcase a selection of our hypercar collection within their exotic car gallery for members and guests in the Carolinas to enjoy. We’re not just partners, but true collaborators, working together to bring CAR SPACE’s unique vision to many cities across the country. Buckle up, because this partnership is going to be a wild ride!”
–  HyperNFT

“This infusion of funds is going to turbocharge our expansion plans and bring our unrivaled concept of blending upscale coworking and a private social club tailored to car aficionados to even more cities. But hold on tight, because there’s more. We’re revving up the excitement by showcasing some of the most coveted hypercars in the world, straight from the HyperNFT collection, at our Raleigh location. Get ready to enjoy a breathtaking array of Bugattis, Koenigseggs, Paganis, and other vehicles that will take your breath away.”
–  Dave Younts, Co-Founder & CEO, CAR SPACE

About HyperNFT
HyperNFT is a highly anticipated members-only club that is set to open in Costa Mesa, California. The club is designed to cater exclusively to owners of supercars and hypercars, providing them with a luxurious and exclusive space to store their prized vehicles. The club will offer a range of premium amenities, including a members lounge, storage facility, and more. Members can expect an unparalleled level of service and a unique community of like-minded individuals who share their passion for high-performance automobiles, making HyperNFT a premier destination for hypercar owners in California.

About Car Space, Inc.
Car Space is a leading provider of luxury, flexible workspace in Raleigh, NC, catering to entrepreneurs, small businesses, and freelancers. Along with its professional and productive environment, Car Space offers a full-service cocktail bar, an exotic car gallery, and event space for individual and corporate members to network, host and socialize. The bar is staffed by experienced mixologists who create signature cocktails, while the car gallery showcases rare and exotic cars from around the world. Car Space also provides amenities such as high-speed internet, a state of the art golf simulator and racing simulators, private meeting rooms and a warming kitchen.

SOURCE CAR SPACE

KNOXVILLE, Tenn., April 27, 2023 — Veteran Ventures Capital’s (“Veteran Ventures”) Veteran Fund I is proud to announce its fourth investment into Phase Four, Inc. (“Phase Four”). Phase Four designs and manufactures cutting-edge plasma-based satellite propulsion systems, providing both commercial and government aerospace and defense clients greater system reliability and flexibility. Veteran Ventures’ management team is especially excited about Phase Four’s recent strides in developing two ground-breaking propulsion designs that have unique and specific national security use cases. With this additional investment, Veteran Ventures joins Phase Four’s Board of Directors.

“We are impressed with Phase Four’s traction in both commercial and national security markets, which fits Veteran Ventures’ dual-use technology thesis perfectly,” explained Steve Kiser, PhD, Veteran Ventures General Partner and new Phase Four board member. “Their technology stack and propulsion product lines are aligned with where their client segments are moving for future satellite propulsion needs. As the U.S. expands its proliferated low-earth orbit constellations and makes greater use of the cis-lunar regime, Phase Four will be leading the way to ensure all on-orbit systems have resilient, advanced maneuvering capabilities that do not rely on outdated legacy technologies nor rely on vulnerable foreign supply chains. They are making ‘maneuver without regret’ a reality.”

“We are proud of our partnership with Veteran Ventures,” remarked Beau Jarvis, CEO of Phase Four. “Their experience in working on critical national security issues within government channels and willingness to work closely with us is refreshing, and we expect more good things to come.”

“It is no secret that the demand for satellite propulsion is large and growing rapidly this decade,” Kiser continued. “Having an established provider of reliable, fuel-agnostic satellite propulsion systems is the key to serving the large volume of satellites being launched into orbit over the next several years. We look forward to working with Phase Four as they scale and deliver the next generation of in-space mobility capabilities for commercial and government spacecraft.”

About Veteran Ventures Capital, LLC

Veteran Ventures is a veteran-owned investment firm focused on investing in veteran leadership and national security dual-use technologies. Veteran Ventures recognizes the value of military experience, training, and character, providing success in all aspects of business growth and operations. For more information, please visit: www.veteranventures.us.

About Phase Four, Inc.

Phase Four is a disruptive provider of next generation electric propulsion (EP) solutions for small satellites. The company was founded in 2015 to address the demands of the rapid proliferation of satellite constellations and to accelerate the advancement of its radio-frequency thruster (RFT). The Phase Four RFT represents a revolutionary new architecture that realizes lower cost, mass-manufacturability, miniaturized power electronics, and propellant agnosticism over incumbent technologies, without compromising performance. In 2021 Phase Four’s Maxwell turn-key propulsion system achieved flight heritage and is now being regularly utilized by small satellite operators. Learn more at www.phasefour.io.

Contact: Craig Jaques
Email: [email protected]

SOURCE Veteran Ventures Capital

LONDON and MIAMI, FL, April 27, 2023 — TympaHealth has raised $23M in Series A funding, led by Octopus Ventures, to expand access to its tech-enabled hearing assessment and diagnostic solution. 

Tympa’s pioneering solution allows for fully digitized comprehensive ear and hearing health assessments to be performed across both traditional clinical and community-based settings. By creating a solution that brings ENT expertise to community settings, Tympa increases cost-effective access to care and supports earlier disease detection. TympaHealth is CE marked, FDA registered, and the only solution of its kind dedicated to the democratization of ear and hearing healthcare. 

The World Health Organization estimates that unaddressed hearing loss costs the global economy $980bn annually due to health sector costs, costs of educational support, loss of productivity, and societal costs. In the UK, over 25% of adults who report hearing problems to their primary care physician are not referred to the National Health Service hearing services or they drop out during the treatment and diagnosis process due to disjointed health pathways. This challenge has expanded since COVID-19 with waiting times for treatment reaching up to one year in the UK. The US Healthcare system faces similar problems with 14% of Americans suffering with some form of hearing loss. Hearing loss is also recognized as the single biggest modifiable risk factor for prevention of dementia and linked to increased falls and social isolation. 

“Our goal is to make ear and hearing healthcare easily accessible to everybody, on a global scale” said Dr Krishan Ramdoo, Founder & CEO of TympaHealth. “Putting the right technology and support into the hands of more healthcare professionals and community providers is the best possible place to start. The Tympa Platform has proven its benefits at every point in the healthcare value chain and with our new funding, we can expand that value to new partners and markets.”

The Tympa Platform allows a much broader range of professionals to perform digital otoscopy, microsuction wax removal, and hearing assessments. Tympa’s comprehensive examination is digitally captured in a single hearing health record, which can be shared between patients, providers, and specialists seamlessly. TympaHealth not only makes ear and hearing health services more accessible to patients, it reduces the time and cost associated with unnecessary primary care and hospital visits.

In the UK, TympaHealth has well established partnerships with providers including Walgreen Boots Alliance, Sonova, Day Lewis Pharmacy, Demant (Hidden Hearing), Bupa, and the NHS to provide treatment through its platform. 

With this funding round, Tympa is growing its team and services in the UK, across Europe and entering into the US. Tympa is also pleased to welcome industry veteran David Horowitz, formerly of Oticon as its new US Vice President of Sales.

With the recent FDA-approval for sale of over-the-counter hearing devices in the US, TympaHealth’s technology enabled service platform is well positioned to support point-of-care providers in non-traditional settings. This support will enable providers to perform fast, accurate and conclusive hearing assessments and also assist patients to make informed decisions about the purchase of hearing devices.  For more advanced diagnoses, Tympa’s cloud computing capabilities enables telehealth consultation for patients requiring specialist support (ENT/Audiology).

The oversubscribed funding round, led by Octopus Ventures, was supported by follow-on investment from existing investors and welcomes new investors Dara Capital, Rezayat investments and serial entrepreneurs Bob Davis and Jeff Leerink. 

Joe Stringer, Partner at Octopus Ventures adds “The TympaHealth proposition is a fantastic exemplar for the quality of high growth healthtech and life science businesses we have in the UK. Using a high-quality product and a proposition geared around the consumer, they are reducing the burden of ear and hearing care in an overstretched NHS, while vastly improving patient experience and outcomes. They are building exactly the kind of game changing business we look to support, and they are in a market with huge potential. We couldn’t be happier to be backing them as they seize that potential and democratize ear and hearing healthcare access globally.”

Dr. Ramdoo said, “This funding round provides us with the opportunity to expand and solve for what is a global problem of hearing loss. We are very excited to be working with Octopus Ventures as we look to scale. We have had a fantastic last year with a significant customer base and to date we have supported more than 250,000 patients. The use of proceeds will be used to accelerate development of key products and services as well as allow for growth into other markets. I am excited about what the future holds, and most importantly, our ongoing dedication to ear and hearing health, made easy.” 

About Octopus Ventures 

For the people and ideas that will change the world, because we believe you can build a better tomorrow by investing in it. We can back you at every stage of your journey, from ideas on a page through to IPO. Each year we deploy more than £200 million across five areas where we see maximum potential for impact: health, fintech, deep tech, consumer and B2B software. With many years of experience and expertise investing in each of these areas, our team can help our portfolio companies scale at speed. For us, investment is about more than money. Being truly invested is about giving time, energy and focus; working with founders to give them the best chance of success. It means a shared commitment to solving the big problems that matter. We’ve backed the likes of ManyPets, Cazoo, Depop, Elvie and WaveOptics, while others have gone on to join forces with the world’s largest businesses. We are based in London and New York with a network of partners across the U.S and Asia.

Visit octopusventures.com

Contact:
Sam Ryan 
[email protected]

Photo: https://mma.prnewswire.com/media/2064820/TympaHealth.jpg

SOURCE TympaHealth

Partnership offers expanded access to non-dilutive funding capital for member companies

KANSAS CITY, Mo., April 27, 2023 — Novel Capital, the fintech growth platform and innovative funding provider helping B2B businesses diversify their funding stack, today announced a partnership with gener8tor that will provide early-stage entrepreneurs with expanded access to non-dilutive financing and education.

Through its partnership with gener8tor, Novel Capital will offer member companies preferred terms and promote the growth benefits of non-dilutive alternative capital options in a startup’s funding strategy. The gener8tor Accelerator program already highlights investment education topics for startup Founders and will expand to include information on alternative capital options.

“gener8tor’s expertise in helping early-stage companies to grow and succeed is second to none, and we are confident that this partnership will give Founders new paths to fuel their capital strategy and growth,” said Keith Harrington, co-founder and COO of Novel Capital.

The partnership between Novel Capital and gener8tor represents a significant opportunity for startups and innovators across the country. Both organizations are committed to serving diverse Entrepreneurs, with over 45% of their respective companies having a minority Founder.

Within gener8tor’s more than 75 offerings, Entrepreneurs also have access to mentorship, coaching, soft skills training and creative art and music workshops.

“gener8tor looks to accelerate those companies that are often overlooked,” said Jeremy Neren, VP Platform & Entrepreneur in Residence of gener8tor. “By forming this partnership with Novel Capital, we’re able to continue our mission to accelerate a diverse range of companies through education and capital access.”

Agtools, an AgTech data platform, aims to reduce food waste and facilitate sustainable supply chain decisions. The company has partnered with gener8tor and Novel Capital separately to reach its growth goals.

“The most valuable asset for any startup is its equity, and Novel’s non-dilutive funding has been a key source of growth for so many companies — ours included,” said Charles Harrison, CFO of Agtools. “We are pleased to learn Novel is collaborating with gener8tor, the accelerator program that empowered us to launch our enterprise sales expansion.”

With access to gener8tor’s community of mentors, resources and investors and Novel Capital’s financial expertise and customizable funding options, entrepreneurs and startups will be better positioned to achieve their growth goals and bring innovative ideas to market.

Alex Linebrink, CEO and Founder of mobile box office technology, Passage adds, “Novel and gener8tor have both been critical partners through the years. The hands-on approach of gener8tor was instrumental in getting us to where we were scaling and fundable. Novel’s non-dilutive capital came at a time when we didn’t have many funding options yet. Both companies have been instrumental in our 345% growth over the last three years, and I can’t wait to see them partnered together to help more startups succeed.”

To learn more, visit Novel Capital’s website and follow the company on LinkedIn. For more information on gener8tor, visit the company’s website and follow them on LinkedIn.

About Novel Capital:
Novel Capital‘s fintech growth platform aims to break down the traditional barriers to growth faced by today’s B2B companies. Their digital experience will allow Founders to leverage future predictable revenue for access to non-dilutive capital, unlock data-driven insights, and act upon data-powered strategies that accelerate growth. The Novel platform empowers Entrepreneurs to capitalize on their momentum.

About gener8tor:
gener8tor is a global venture firm and accelerator network that supports startups, workers, employers, artists and musicians across race, place and gender. gener8tor partners with companies, governments, universities and nonprofits to operate programs and conferences in more than 41 communities across 22 states and two countries. Fast Company named gener8tor one of the Best Workplaces for Innovators in 2021 and 2022. The International Trade Council recognized gener8tor as the Global Venture Capital Firm of the Year in 2022.

Media Contact:
Emylee Eyler
BLASTmedia for Novel Capital
[email protected]
317.806.1900 ext. 139

SOURCE Novel Capital

AURORA, Colo., April 27, 2023 — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. The proceeds will be used to accelerate the clinical development and commercialization of Foresight Diagnostics’ cancer recurrence testing platform, PhasED-Seq™.

“We are excited and honored to be working with Jim Tananbaum, Vik Bajaj, Uplaksh Kumar, and the Foresite Capital team,” said Jake Chabon, Ph.D., CEO and co-founder of Foresight Diagnostics. “Foresite Capital brings significant operational and investment experience in cancer diagnostics and the minimal residual disease (MRD) market and are an excellent partner for us as we pursue our mission to improve the lives of cancer patients. This next chapter in our growth will be focused on expanding our support of pharmaceutical partners, furthering the clinical and regulatory claims associated with our platform, and bringing our tests to patients. For our pharma partners, these increased capabilities will support both translational research and prospective clinical trials.”

Foresight’s patented PhasED-Seq technology leverages the sequencing of phased variants for ultrasensitive and highly specific detection of circulating tumor DNA (ctDNA). The approach enhances sensitivity and specificity by requiring the concordant detection of two or more distinct somatic mutations within a single DNA molecule, enabling detection of MRD ctDNA at levels below one part-per-million (<0.0001%). Over 20 clinical studies using Foresight’s technology have been published across both liquid and solid tumors and have been presented at major clinical oncology meetings such as AACR, ASCO, ASH and ICML. Following a $12.5M Series A financing, Foresight initially focused on evidence generation in patients with B-cell malignancies and PhasED-Seq has now been extensively validated in this clinical setting, including multiple studies presented at the 2022 ASH annual meeting.

More recently, the company has expanded their efforts to demonstrate the utility of their MRD testing platform in patients with solid tumors. Earlier this month at the annual meeting of the American Association for Cancer Research (AACR 2023), Foresight presented data generated using their Solid Tumor Recurrence Test showing that PhasED-Seq achieved a high confidence limit of detection (LOD95) of one part-per-million or below in the majority of blood samples. This improvement in analytical sensitivity corresponded to an approximately two-fold improvement in clinical sensitivity for MRD detection following surgery in patients with early-stage lung cancer who later relapsed compared to prior results generated using first generation SNV-based MRD approaches.

As part of this funding, Uplaksh Kumar, Ph.D., will be joining the Foresight Diagnostics board of directors. Dr. Kumar is a Venture Partner at Foresite Capital, and brings extensive experience in cancer diagnostics and operations, having formerly worked as the SVP of strategic operations and scale at GRAIL, where he launched Galleri®, the first of its kind early detection blood test. Prior to his role at GRAIL, Uplaksh was the first head of operations at Verily, and has held various leadership positions at Life Technologies, BD, LONZA, and Qiagen.

“I’ve been extremely impressed by the achievements that Foresight has made towards redefining cancer treatment and the drug development process through precision cancer monitoring,” said Kumar. “I look forward to leveraging my operational experience to help commercialize Foresight’s MRD testing platform.”

“We’re delighted to have Dr. Kumar join Foresight’s board of directors, where he will join the company’s founders, Genentech’s former SVP and Global Head for Personalized Healthcare Mark Lee, and myself as we work to improve the lives of cancer patients through innovative diagnostics,” stated Shahram Seyedin-Noor, founder and General Partner at Civilization Ventures.

About Foresight Diagnostics
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests (with a detection limit below 0.0001%, or one part-per-million). The improved sensitivity of the Foresight’s MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on Twitter and LinkedIn.  

About PhasED-Seq
The Foresight MRD platform is based on the Phased variant Enrichment and Detection by Sequencing (PhasED-Seq™) technology. PhasED-Seq lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%). PhasED-Seq has been extensively validated in thousands of patient samples.

About Foresite Capital
Foresite Capital is a multi-stage healthcare and life sciences investment firm with approximately $3.5 billion in assets under management. The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City. For more information, please visit www.foresitecapital.com.

Contact Foresight 
Phone: 720-443-3658 
Email: [email protected] 

SOURCE Foresight Diagnostics

Funding was led by Five Elms Capital.

TORONTO, April 27, 2023 — Practice Better, a leading, all-in-one practice management software platform for health and wellness professionals, announced today that it has raised a $27 million growth investment led by Five Elms Capital and follows a $1 million investment from Disruption Ventures in 2021. The investment will support the development of new integrations and strategic partnerships, as well as enhanced product features to help health professionals sustainably scale their businesses and deliver better client care. The company plans to invest in expanding its go-to-market (GTM), customer-facing, and tech teams to better support its growing customer base.

“Practice Better was born from a need to solve my own challenge to sustainably build a client-centric nutrition practice, without sacrificing my well-being,” said Nathalie Garcia, Founder of Practice Better. “This investment comes at a critical time as conventional medicine models are under tremendous pressure and the demand for proactive, alternative forms of wellness care is on the rise. I’m excited to continue to evolve the platform, grow our team, and expand into new verticals.”

Founded in 2016, Practice Better offers comprehensive practice management software for health and wellness practitioners. Its features include scheduling and appointment management, telehealth, charting, billing, client engagement, online programs, payment processing, and more. The platform is designed to help practitioners who want to save time, reduce administrative burdens, and provide better care to their clients. 

“Nathalie and the Practice Better team have experienced remarkable growth over the past six years. With over 65% of its customer growth coming from word of mouth and referrals, Practice Better has recorded a 300% compound annual growth rate (CAGR) since inception,” said Austin Gideon, Partner at Five Elms Capital. “When Practice Better was founded in 2016, it was entering a market in desperate need of innovation. Since then, the team has committed to doing things differently by putting client outcomes at the forefront of health and wellness technology and allowing the industry to break free of outdated and unscalable models. Its reputation as a disruptive force comes from years of dedication, and Five Elms Capital is thrilled to support its continued growth.”

“This funding unlocks the potential to expand our product capabilities and welcomes new strategic partnerships that will further enable our customers to deliver more supportive wellness care,” added Garcia. “In order for our customers to be successful, their clients need to be successful. We are uniquely positioned to enable more sustainable and collaborative wellness care”.

About Practice Better
Practice Better is a leading all-in-one practice management software solution transforming how health & wellness professionals run their practices and support their clients. The company serves 10,000+ customers in over 70+ countries across the globe, and processes hundreds of millions annually in payments on behalf of customers. In addition to supporting thousands of nutrition-focused practitioners and coaches, Practice Better has seen incredible adoption from other verticals within the health and wellness space including naturopathic doctors, chiropractors, mental health therapists, and other wellness professionals. Its platform empowers wellness professionals to streamline admin work, engage clients, and scale their practices beyond the traditional 1:1 model. Its consistent, best-in-class NPS score and organic growth from word-of-mouth referrals are a testament to its happy customers. For more information, visit practicebetter.io 

About Five Elms Capital
Five Elms Capital is a leading growth investor in world-class software businesses that users love. Five Elms provides capital and resources to help companies accelerate growth and further cement their role as industry leaders. Five Elms maintains offices in North America and Europe and invests in the best software platforms globally. For more information, visit fiveelms.com.

Media Contact:
Renee Rossi
[email protected]

SOURCE Practice Better

SINGAPORE, April 27, 2023 — EMURGO VENTURES (“EMV”) – EMURGO Ventures, the investment arm of Cardano blockchain founding entity EMURGO, today officially announced the Cardano EMURGO BUILD 2023 Hackathon event in partnership with DoraHacks, the world’s most active multi-chain Web3 developer community.

The Cardano EMURGO BUILD 2023 Hackathon is the largest ever Cardano blockchain-focused Web3 hackathon organized by a Cardano founding entity and will award up to $2 million in total prizes to winning participants. The hackathon will have three different tracks for participants to build their prototypes: DeFi derivatives, aggregators, and zero-knowledge (ZK). Submissions will be decided by a panel of judges from EMURGO including founder and CEO Ken Kodama, EMURGO Ventures, Cardano Foundation, Input Output Global (IOG), Binance, Republic Crypto, and Wave Financial. Participation is open to anyone interested in building decentralized applications (dApps) on Cardano, including developers, designers, and entrepreneurs.

Cardano EMURGO BUILD 2023 Hackathon will be hosted virtually and submissions will be accepted starting in early May 2023. It will be held over several weeks to allow time for participants to research, build, and submit their solutions. EMURGO and DoraHacks will also feature video workshops during the hackathon period to help participants build their Web3 projects.

“EMURGO is thrilled to host a large hackathon for the Cardano ecosystem with the support of DoraHacks and our partners. Cardano has been one of the leading blockchain networks for developer activity over the past few years which shows the high interest in building the Cardano ecosystem,” said EMURGO founder and CEO Ken Kodama. “Cardano EMURGO BUILD 2023 provides a great opportunity for anyone in the world to demonstrate their talents.”

“Cardano is one of the largest web3 ecosystems in the world. As a chain-agnostic developer community and hackathon infrastructure, DoraHacks is keen to support builders and early-stage projects from the Cardano ecosystem,” said DoraHacks Head of BD Steve Ngok. “We are excited to work with EMURGO and Cardano for the first time through a flagship virtual hackathon, and looking forward to bringing long-term value to the ecosystem.”

Registration and more submission details are here.

Interested participants can also join the official Discord channel here.

About EMURGO Ventures
EMURGO Ventures (“EMV’) is the venture capital and investment arm of EMURGO, the official commercial arm and a founding entity of the Cardano blockchain. EMV focuses on investing in and supporting innovative Web3 projects and startups that have the potential to drive the adoption and integration of blockchain technology across various industries. Through strategic partnerships and investments, EMV is working to expand the possibilities of blockchain technology and bring it closer to mainstream adoption, while also contributing to the growth and development of the broader blockchain community.

To learn more, please visit https://emurgo.io.

For more information:
Albert Kim
Global PR Manager
[email protected]
+65 6978 5823

About DoraHacks
DoraHacks is a global hackathon organizer and one of the world’s most active multi-chain Web3 developer platforms. It creates a global hacker movement and provides crypto-native toolkits to help developers around the world team up and fund their ideas and BUIDLs via hackathons, bounties, grants, grant DAOs, and public good staking. By far, more than 4000 projects from the DoraHacks community have received over $30 million in grants and other forms of contributions from supporters worldwide. A large number of open-source communities, DAOs, and more than 50 major blockchain ecosystems are actively using Dora’s infrastructure for open-source funding and community governance.

For more information, please visit https://dorahacks.io

For more information:
Steve Ngok
Head of Business Development
[email protected]

SOURCE EMURGO Ventures